
This study was conducted to assess the safety, zzso zzso and zzso of the zzso zzso zzso inhibitor zzso zzso in patients with advanced solid zzso 

In part 1, patients received escalating doses of zzso zzso infusion every 14 zzso without zzso zzso zzso factor, zzso zzso zzso was the zzso toxicity without zzso Further dose escalation was done in part 2 with zzso Blood samples were collected for zzso zzso and zzso zzso zzso were collected to assess zzso zzso zzso zzso 

zzso patients were treated, 40 in part 1 and 16 in part zzso zzso zzso was the zzso toxicity in part 1 without zzso Most other adverse events were grade 1 to 2, occurring at doses zzso zzso with similar zzso in parts 1 and zzso The maximum tolerated dose without zzso is 500 zzso The recommended phase 2 dose in part 2 with zzso is 750 zzso zzso showed zzso zzso in parts 1 and 2 with a median zzso of 18 to 26 zzso zzso zzso in skin zzso was observed at zzso zzso One patient with zzso small cell lung cancer zzso zzso with zzso had an objective response lasting 23 zzso One patient with zzso zzso cancer had zzso tumor zzso and zzso zzso zzso 

zzso was well tolerated with target zzso in skin at zzso zzso zzso evidence of zzso activity, including a partial response and several zzso of prolonged stable disease, was seen across a variety of advanced zzso zzso Phase II studies are zzso 

